Cara Therapeutics, Inc. reports statistically significant topline results from its Phase 2 trial of its […]
The CURE Blog
Great article by Fred Spaeth, partner at Dilworth IP.
“On June 22, 2015 in Kimble v. […]
CURE and BioHaven Present Achillion: Transforming Innovation into Novel Therapies to Address Patient Needs
Presenting: Dr. Milind Deshpande
Based in New Haven, Connecticut since 2001, Achillion Pharmaceuticals devotes their efforts […]